文献速递脑血管病

F2R基因多态性与氯吡格雷在轻型卒中或TIA患者中的疗效和安全性

F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA.
PubMed 文献 · Neurology · 2020-10-22

本研究基于2924例轻型卒中或TIA患者,探讨PAR-1基因F2R多态性与氯吡格雷疗效的关系。结果显示,携带F2R IVSn-14 T等位基因的患者接受氯吡格雷联合阿司匹林治疗较单用阿司匹林新发卒中风险更低,而AA基因型者未见获益,且该效应不受CYP2C19功能缺失等位基因影响。

要点

  • F2R IVSn-14 T等位基因携带者可从氯吡格雷联合阿司匹林治疗中获益。
  • AA基因型患者接受氯吡格雷联合阿司匹林未显示降低新发卒中风险。
  • F2R多态性与氯吡格雷治疗出血风险无关。

核心结论

  • 携带F2R IVSn-14 T等位基因的轻型卒中或TIA患者,接受氯吡格雷联合阿司匹林治疗较单用阿司匹林新发卒中风险更低。

研究设计与样本

  • 研究纳入2924例轻型卒中或TIA患者,随机分为氯吡格雷联合阿司匹林组(n=1461)和阿司匹林单药组(n=1463),对CYP2C19*2、CYP2C19*3和F2R IVSn-14进行基因分型。

主要发现

  • F2R IVSn-14基因型分布:AA纯合子859例(29.4%),AT杂合子1479例(50.6%),TT纯合子586例(20.0%)。
  • CYP2C19功能缺失等位基因(*2或*3)携带者1716例(58.7%)。
  • 与单用阿司匹林相比,氯吡格雷联合阿司匹林降低新发卒中风险:AT基因型7.6% vs 11.3%(HR 0.63,95%CI 0.44-0.89),TT基因型5.8% vs 11.6%(HR 0.46,95%CI 0.25-0.82),AA基因型10.8% vs 11.6%(HR 0.95,95%CI 0.63-1.44),交互作用P=0.03。
  • F2R IVSn-14多态性与氯吡格雷疗效的关联不受CYP2C19功能缺失等位基因携带状态影响。
  • F2R IVSn-14基因型与氯吡格雷联合阿司匹林治疗的任何出血风险无关(交互作用P=0.66)。

临床怎么用

  • 对于轻型卒中或TIA患者,检测F2R IVSn-14多态性可能有助于识别从氯吡格雷联合阿司匹林治疗中获益更多的人群。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the association between protease-activated receptor-1 (PAR-1) gene F2R polymorphisms and efficacy of clopidogrel for minor stroke or TIA. METHODS: Three single nucleotide polymorphisms (CYP2C19*2 [681G>A, rs4244285], CYP2C19*3 [636G>A, rs4986893], and F2R [IVSn-14 A/T, rs168753]) were genotyped among 2,924 patients randomized to clopidogrel plus aspirin (n = 1,461) or aspirin alone (n = 1,463). The primary efficacy outcome was new stroke (ischemic or hemorrhagic) and the safety outcome was any bleeding. RESULTS: Overall, 859 (29.4%) were AA homozygotes, 1,479 (50.6%) were AT heterozygotes, and 586 (20.0%) were TT homozygotes for F2R IVSn-14 polymorphisms; 1,716 (58.7%) were carriers of at least 1 CYP2C19 loss-of-function allele (*2 or *3). Compared with aspirin alone, patients with clopidogrel-aspirin treatment had a low risk of new stroke in patients with AT genotype (7.6% vs 11.3%; hazard ratio [HR], 0.63; 95% confidence interval [CI], 0.44-0.89) and TT genotype (5.8% vs 11.6%; HR, 0.46; 95% CI, 0.25-0.82) but not in carriers of the AA genotype (10.8% vs 11.6%; HR, 0.95; 95% CI, 0.63-1.44) (p = 0.03 for interaction). The association between F2R IVSn-14 A/T polymorphism and clopidogrel response was present regardless of the carrier status of the CYP2C19 loss-of-function alleles. The F2R IVSn-14 genotypes were not associated with the risk of any bleeding for clopidogrel-aspirin treatment (p = 0.66 for interaction). CONCLUSIONS: Among patients with minor ischemic stroke or TIA who were receiving clopidogrel and aspirin, those carrying the F2R IVSn-14 T allele had a lower rate of recurrent stroke than those who were not. CLINICALTRIALSGOV IDENTIFIER: NCT00979589.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Pan Y, Wangqin R, Li H, et al. F2R Polymorphisms and Clopidogrel Efficacy and Safety in Patients With Minor Stroke or TIA. Neurology. 2020. PMID: 33093222. doi:10.1212/WNL.0000000000011078

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。